TY - JOUR
T1 - Antiangiogenesis mediates cisplatin-induced peripheral neuropathy attenuation or reversal by local vascular endothelial growth factor gene therapy without augmenting tumor growth
AU - Kirchmair, Rudolf
AU - Walter, Dirk H.
AU - Ii, Masaaki
AU - Rittig, Kilian
AU - Tietz, Anne B.
AU - Murayama, Toshinori
AU - Emanueli, Costanza
AU - Silver, Marcy
AU - Wecker, Andrea
AU - Amant, Carole
AU - Schratzberger, Peter
AU - Yoon, Young Sup
AU - Weber, Alberto
AU - Panagiotou, Eleftheria
AU - Rosen, Kenneth M.
AU - Bahlmann, Ferdinand H.
AU - Adelman, Lester S.
AU - Weinberg, David H.
AU - Ropper, Allan H.
AU - Isner, Jeffrey M.
AU - Losordo, Douglas W.
PY - 2005/5/24
Y1 - 2005/5/24
N2 - Background - Toxic neuropathies induced by cisplatin and other chemotherapeutic agents are important clinical problems because of their high incidence, their lack of effective treatment, and the fact that neuropathy represents a dose-limiting factor for these therapies. The pathogenic basis for toxic neuropathies induced by chemotherapeutic agents has not been completely elucidated. Methods and Results - We investigated the hypothesis that experimental toxic neuropathy results from an antiangiogenic effect of these drugs, resulting in destruction of the vasa nervorum, and accordingly that the neuropathy could be prevented or reversed by locally administered VEGF gene transfer without augmenting tumor growth. In an animal model of cisplatin-induced neuropathy, nerve blood flow was markedly attenuated, and there was a profound reduction in the number of vasa nervorum associated with marked endothelial cell apoptosis, resulting in a severe peripheral neuropathy with focal axonal degeneration characteristic of ischemic neuropathy. After intramuscular gene transfer of naked plasmid DNA encoding VEGF-1 in animals with an established neuropathy, vascularity and blood flow returned to levels similar to those of control rats, peripheral nerve function was restored, and histological nerve architecture was normalized. Gene therapy administered in parallel with cisplatin chemotherapy completely attenuated endothelial cell apoptosis and inhibited destruction of nerve vasculature, deterioration of nerve function, and axonal degeneration. In a rat tumor model, VEGF gene transfer administered locally did not alter tumor growth or vascularity. Conclusions - These findings implicate microvascular damage as the basis for toxic neuropathy induced by cisplatin and suggest that local angiogenic gene therapy may constitute a novel prevention or treatment for this disorder without augmenting tumor growth or vascularization.
AB - Background - Toxic neuropathies induced by cisplatin and other chemotherapeutic agents are important clinical problems because of their high incidence, their lack of effective treatment, and the fact that neuropathy represents a dose-limiting factor for these therapies. The pathogenic basis for toxic neuropathies induced by chemotherapeutic agents has not been completely elucidated. Methods and Results - We investigated the hypothesis that experimental toxic neuropathy results from an antiangiogenic effect of these drugs, resulting in destruction of the vasa nervorum, and accordingly that the neuropathy could be prevented or reversed by locally administered VEGF gene transfer without augmenting tumor growth. In an animal model of cisplatin-induced neuropathy, nerve blood flow was markedly attenuated, and there was a profound reduction in the number of vasa nervorum associated with marked endothelial cell apoptosis, resulting in a severe peripheral neuropathy with focal axonal degeneration characteristic of ischemic neuropathy. After intramuscular gene transfer of naked plasmid DNA encoding VEGF-1 in animals with an established neuropathy, vascularity and blood flow returned to levels similar to those of control rats, peripheral nerve function was restored, and histological nerve architecture was normalized. Gene therapy administered in parallel with cisplatin chemotherapy completely attenuated endothelial cell apoptosis and inhibited destruction of nerve vasculature, deterioration of nerve function, and axonal degeneration. In a rat tumor model, VEGF gene transfer administered locally did not alter tumor growth or vascularity. Conclusions - These findings implicate microvascular damage as the basis for toxic neuropathy induced by cisplatin and suggest that local angiogenic gene therapy may constitute a novel prevention or treatment for this disorder without augmenting tumor growth or vascularization.
UR - http://www.scopus.com/inward/record.url?scp=21144445380&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=21144445380&partnerID=8YFLogxK
U2 - 10.1161/CIRCULATIONAHA.104.470849
DO - 10.1161/CIRCULATIONAHA.104.470849
M3 - Article
C2 - 15897348
AN - SCOPUS:21144445380
SN - 0009-7322
VL - 111
SP - 2662
EP - 2670
JO - Circulation
JF - Circulation
IS - 20
ER -